Christopher Gibson - 01 Sep 2022 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Footnote F1

Transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

Footnote F2

This transaction was executed in multiple trades at prices ranging from $10.17 to $10.26. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Footnote F3

Represents the conversion of Class B Common Stock into Class A Common Stock.

Footnote F4

This transaction was executed in multiple trades at prices ranging from $10.12 to $10.89. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Footnote F5

The shares are held by LAHWRAN-3 LLC, of which the Reporting Person is a member and a manager.

Footnote F6

This transaction was executed in multiple trades at prices ranging from $10.25 to $10.89. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Footnote F7

The shares are held by LAHWRAN-4 LLC, of which the Reporting Person is a member and a manager.

Footnote F8

This transaction was executed in multiple trades at prices ranging from $10.23 to $10.89. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Footnote F9

The shares are held by the Gibson Family Trust, of which the Reporting Person serves as Trustee.

Footnote F10

Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.

Footnote F11

The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.

Footnote F12

The option, originally for 1,500,000 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on January 31, 2021, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.